Sodium-glucose cotransporter 2 inhibitors (SGLT2i)

DRUG2 trials

Sponsors

Bayer, University of Pennsylvania

Conditions

Chronic Kidney DiseaseDiabetes Mellitus, Type 2Diabetic NephropathiesKidney DiseasesRenal Insufficiency, ChronicType 2 Diabetes Mellitus

Unknown Phase

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

CompletedNCT05526157

BayerChronic Kidney Disease, Type 2 Diabetes Mellitus

Start: 2022-10-01End: 2024-09-05Updated: 2024-10-15

Transformative Research in Diabetic Nephropathy 2.0

RecruitingNCT07444203

University of PennsylvaniaDiabetes Mellitus, Type 2, Diabetic Nephropathies, Kidney Diseases +1

Start: 2025-11-12End: 2028-11-12Target: 200Updated: 2026-03-02

Related Papers

Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.

2025-12-09

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.

2025-03-191 citations

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study.

2024-12-172 citations

#2505 CHARACTERISTICS OF MEDICATION-INITIATOR COHORTS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES IN JAPAN: A REPORT FROM FOUNTAIN PLATFORM

Nephrology Dialysis Transplantation2023-06-01